Anonymousabout 3 hours ago
Drug-resistant Clostridioides difficile infections are rising in the United States, fueled by pandemic-era antibiotic overuse and declining treatment efficacy, with an estimated annual economic burden exceeding $6 billion. While community-acquired cases now account for more than half of all infections and reduced vancomycin susceptibility is appearing in up to 29% of clinical isolates, experts disagree on whether the resistance threat constitutes a true clinical crisis or reflects modest laboratory shifts that existing treatment protocols can still manage.